Analysts’ Weekly Ratings Changes for Dianthus Therapeutics (DNTH)

Posted by on Jun 23rd, 2026

Dianthus Therapeutics (NASDAQ: DNTH) recently received a number of ratings updates from brokerages and research firms:

  • 6/10/2026 – Dianthus Therapeutics had its “buy” rating reaffirmed by Guggenheim.
  • 6/10/2026 – Dianthus Therapeutics had its “buy” rating reaffirmed by TD Cowen.
  • 6/10/2026 – Dianthus Therapeutics had its “strong-buy” rating reaffirmed by Raymond James Financial, Inc..
  • 6/10/2026 – Dianthus Therapeutics had its “outperform” rating reaffirmed by Wolfe Research.
  • 5/9/2026 – Dianthus Therapeutics was upgraded by Wall Street Zen from “sell” to “hold”.
  • 5/6/2026 – Dianthus Therapeutics had its price target raised by Wedbush from $103.00 to $105.00. They now have an “outperform” rating on the stock.

Insider Activity at Dianthus Therapeutics

In related news, EVP Simrat Randhawa sold 26,530 shares of the stock in a transaction on Monday, June 1st. The stock was sold at an average price of $90.62, for a total transaction of $2,404,148.60. Following the sale, the executive vice president owned 4,000 shares of the company’s stock, valued at $362,480. This trade represents a 86.90% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, SVP Adam M. Veness sold 30,000 shares of Dianthus Therapeutics stock in a transaction dated Wednesday, June 17th. The stock was sold at an average price of $80.80, for a total value of $2,424,000.00. Following the sale, the senior vice president owned 30,000 shares of the company’s stock, valued at approximately $2,424,000. This represents a 50.00% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold a total of 179,121 shares of company stock valued at $15,059,454 over the last quarter. Insiders own 3.02% of the company’s stock.

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc was founded in 2019 and is headquartered in New York, New York.

Featured Stories

Receive News & Ratings for Dianthus Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dianthus Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.